| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Uterine Cervical Neoplasms | 11 | 2018 | 842 | 1.66 | Why? |
| Osteosarcoma | 2 | 2018 | 83 | 1.35 | Why? |
| Methotrexate | 2 | 2018 | 471 | 1.05 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2018 | 1573 | 0.95 | Why? |
| Neoplasms, Glandular and Epithelial | 2 | 2018 | 39 | 0.88 | Why? |
| Carcinoma, Squamous Cell | 4 | 2018 | 902 | 0.88 | Why? |
| Mandatory Testing | 1 | 2020 | 67 | 0.84 | Why? |
| Adenocarcinoma, Clear Cell | 1 | 2017 | 8 | 0.73 | Why? |
| WT1 Proteins | 1 | 2017 | 15 | 0.73 | Why? |
| Cystadenocarcinoma, Serous | 1 | 2017 | 18 | 0.73 | Why? |
| Aspartic Acid Endopeptidases | 1 | 2017 | 57 | 0.72 | Why? |
| Cisplatin | 5 | 2018 | 209 | 0.68 | Why? |
| Chemoradiotherapy | 6 | 2018 | 362 | 0.67 | Why? |
| Textiles | 1 | 2020 | 458 | 0.59 | Why? |
| Particle Size | 1 | 2020 | 1052 | 0.58 | Why? |
| Ovarian Neoplasms | 2 | 2018 | 465 | 0.58 | Why? |
| Brachytherapy | 4 | 2018 | 93 | 0.55 | Why? |
| Bone Neoplasms | 1 | 2017 | 287 | 0.53 | Why? |
| Progesterone | 3 | 2018 | 106 | 0.49 | Why? |
| Breast Neoplasms | 10 | 2021 | 3633 | 0.45 | Why? |
| Neoadjuvant Therapy | 4 | 2018 | 554 | 0.45 | Why? |
| Receptors, Progesterone | 3 | 2017 | 76 | 0.39 | Why? |
| Paclitaxel | 3 | 2018 | 124 | 0.39 | Why? |
| Neoplasm Staging | 8 | 2019 | 1999 | 0.38 | Why? |
| Radiotherapy, Intensity-Modulated | 2 | 2018 | 148 | 0.35 | Why? |
| India | 15 | 2021 | 11875 | 0.32 | Why? |
| Chemotherapy, Adjuvant | 3 | 2018 | 606 | 0.31 | Why? |
| Neoplasms | 7 | 2021 | 17251 | 0.24 | Why? |
| Disease-Free Survival | 5 | 2018 | 1654 | 0.24 | Why? |
| Neoplasm Recurrence, Local | 3 | 2018 | 1063 | 0.23 | Why? |
| Carboplatin | 2 | 2018 | 76 | 0.22 | Why? |
| Ethylene Oxide | 1 | 2020 | 55 | 0.22 | Why? |
| Progestins | 2 | 2017 | 43 | 0.22 | Why? |
| Polypropylenes | 1 | 2020 | 121 | 0.21 | Why? |
| Neoplasm Grading | 2 | 2019 | 400 | 0.21 | Why? |
| Financing, Personal | 1 | 2021 | 113 | 0.20 | Why? |
| Hysterectomy | 2 | 2018 | 171 | 0.20 | Why? |
| Receptor, ErbB-2 | 2 | 2018 | 267 | 0.19 | Why? |
| Desmosomes | 1 | 2018 | 6 | 0.19 | Why? |
| Hemolysin Proteins | 1 | 2018 | 21 | 0.19 | Why? |
| Radiotherapy, Conformal | 1 | 2018 | 49 | 0.19 | Why? |
| Hyaluronan Receptors | 1 | 2018 | 61 | 0.19 | Why? |
| Ifosfamide | 1 | 2017 | 10 | 0.18 | Why? |
| Human papillomavirus 18 | 1 | 2017 | 36 | 0.18 | Why? |
| Phosphotransferases | 1 | 2017 | 16 | 0.18 | Why? |
| Spectrum Analysis, Raman | 1 | 2020 | 311 | 0.18 | Why? |
| Deoxycytidine | 1 | 2018 | 116 | 0.17 | Why? |
| Masks | 1 | 2020 | 8528 | 0.17 | Why? |
| Endometrial Neoplasms | 1 | 2019 | 120 | 0.17 | Why? |
| Neoplastic Stem Cells | 1 | 2018 | 120 | 0.17 | Why? |
| Human papillomavirus 16 | 1 | 2017 | 95 | 0.17 | Why? |
| Cytoreduction Surgical Procedures | 1 | 2018 | 144 | 0.16 | Why? |
| Neoplasms, Multiple Primary | 1 | 2017 | 61 | 0.16 | Why? |
| Neoplasms, Second Primary | 1 | 2017 | 100 | 0.16 | Why? |
| Survival Rate | 4 | 2020 | 9206 | 0.16 | Why? |
| Mycobacterium Infections | 1 | 2017 | 72 | 0.16 | Why? |
| Cell Movement | 2 | 2018 | 695 | 0.16 | Why? |
| Esthetics | 1 | 2017 | 136 | 0.16 | Why? |
| Graft vs Host Disease | 1 | 2021 | 501 | 0.16 | Why? |
| Antiemetics | 1 | 2017 | 75 | 0.16 | Why? |
| Bacterial Toxins | 1 | 2018 | 185 | 0.16 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.16 | Why? |
| Carcinogenesis | 1 | 2018 | 236 | 0.15 | Why? |
| Tumor Burden | 1 | 2017 | 369 | 0.15 | Why? |
| Carcinoma, Ductal, Breast | 1 | 2017 | 149 | 0.15 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.15 | Why? |
| Intention to Treat Analysis | 1 | 2017 | 673 | 0.15 | Why? |
| Heat-Shock Proteins | 1 | 2018 | 226 | 0.15 | Why? |
| Doxorubicin | 1 | 2017 | 313 | 0.14 | Why? |
| Neoplasm Metastasis | 1 | 2018 | 682 | 0.14 | Why? |
| Anemia, Iron-Deficiency | 1 | 2017 | 210 | 0.14 | Why? |
| Filtration | 1 | 2020 | 820 | 0.14 | Why? |
| Tertiary Healthcare | 1 | 2018 | 616 | 0.13 | Why? |
| Humidity | 1 | 2020 | 944 | 0.13 | Why? |
| Female | 33 | 2021 | 380317 | 0.13 | Why? |
| Kaplan-Meier Estimate | 3 | 2018 | 4260 | 0.13 | Why? |
| Herpesvirus 4, Human | 1 | 2017 | 387 | 0.13 | Why? |
| Nausea | 1 | 2017 | 457 | 0.13 | Why? |
| Middle Aged | 27 | 2021 | 270681 | 0.13 | Why? |
| Stress, Physiological | 1 | 2018 | 378 | 0.13 | Why? |
| Treatment Outcome | 10 | 2018 | 51732 | 0.13 | Why? |
| Wound Healing | 1 | 2017 | 424 | 0.13 | Why? |
| Health Expenditures | 1 | 2021 | 904 | 0.13 | Why? |
| Policy | 1 | 2021 | 1372 | 0.12 | Why? |
| Prospective Studies | 7 | 2020 | 43301 | 0.12 | Why? |
| Epstein-Barr Virus Infections | 1 | 2017 | 366 | 0.12 | Why? |
| RNA Viruses | 1 | 2020 | 824 | 0.12 | Why? |
| Hot Temperature | 1 | 2020 | 1299 | 0.12 | Why? |
| Vomiting | 1 | 2017 | 722 | 0.12 | Why? |
| Combined Modality Therapy | 2 | 2018 | 3395 | 0.11 | Why? |
| Iron | 1 | 2017 | 619 | 0.11 | Why? |
| Mouth Neoplasms | 1 | 2018 | 463 | 0.11 | Why? |
| Adult | 23 | 2021 | 244371 | 0.11 | Why? |
| Humans | 41 | 2021 | 930598 | 0.11 | Why? |
| Pancreatic Neoplasms | 1 | 2018 | 609 | 0.11 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.11 | Why? |
| Exosomes | 1 | 2017 | 567 | 0.11 | Why? |
| Preoperative Care | 1 | 2020 | 1515 | 0.10 | Why? |
| Immunohistochemistry | 1 | 2017 | 2275 | 0.10 | Why? |
| Cost of Illness | 1 | 2021 | 1903 | 0.10 | Why? |
| Papillomavirus Infections | 1 | 2017 | 861 | 0.09 | Why? |
| Geriatric Assessment | 1 | 2017 | 1372 | 0.09 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.09 | Why? |
| Aged | 19 | 2021 | 215776 | 0.08 | Why? |
| Seasons | 1 | 2020 | 4071 | 0.08 | Why? |
| Noncommunicable Diseases | 1 | 2017 | 934 | 0.08 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.08 | Why? |
| Disinfection | 1 | 2020 | 2912 | 0.08 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 2426 | 0.08 | Why? |
| Radiotherapy Dosage | 2 | 2018 | 428 | 0.08 | Why? |
| Adolescent | 6 | 2020 | 86841 | 0.08 | Why? |
| Neoplasm Invasiveness | 2 | 2019 | 582 | 0.08 | Why? |
| Blotting, Western | 2 | 2018 | 863 | 0.07 | Why? |
| Young Adult | 8 | 2020 | 93724 | 0.07 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.07 | Why? |
| Fluorescent Antibody Technique | 2 | 2018 | 835 | 0.07 | Why? |
| Developing Countries | 2 | 2017 | 4283 | 0.07 | Why? |
| Immunotherapy | 1 | 2018 | 2421 | 0.07 | Why? |
| MicroRNAs | 1 | 2017 | 1787 | 0.07 | Why? |
| Aerosols | 1 | 2020 | 5393 | 0.07 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.06 | Why? |
| Male | 11 | 2021 | 367725 | 0.06 | Why? |
| Mastectomy | 2 | 2018 | 536 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
| Viral Load | 2 | 2021 | 15850 | 0.06 | Why? |
| Tertiary Care Centers | 2 | 2018 | 8248 | 0.06 | Why? |
| Elective Surgical Procedures | 1 | 2020 | 5338 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.06 | Why? |
| Retrospective Studies | 6 | 2018 | 105322 | 0.06 | Why? |
| Literacy | 1 | 2021 | 53 | 0.06 | Why? |
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 1014 | 0.05 | Why? |
| Child | 3 | 2020 | 70012 | 0.05 | Why? |
| Marital Status | 1 | 2021 | 186 | 0.05 | Why? |
| Ambulatory Care | 1 | 2017 | 4947 | 0.05 | Why? |
| Octamer Transcription Factor-3 | 1 | 2018 | 17 | 0.05 | Why? |
| SOXB1 Transcription Factors | 1 | 2018 | 20 | 0.05 | Why? |
| gamma Catenin | 1 | 2018 | 3 | 0.05 | Why? |
| Desmoglein 2 | 1 | 2018 | 5 | 0.05 | Why? |
| Desmoplakins | 1 | 2018 | 6 | 0.05 | Why? |
| Carcinoma, Adenosquamous | 1 | 2017 | 17 | 0.05 | Why? |
| Cell Line, Tumor | 2 | 2017 | 3608 | 0.05 | Why? |
| Electrophoresis, Polyacrylamide Gel | 1 | 2018 | 238 | 0.04 | Why? |
| Surgical Wound Dehiscence | 1 | 2017 | 18 | 0.04 | Why? |
| Hematinics | 1 | 2017 | 48 | 0.04 | Why? |
| Antineoplastic Agents | 3 | 2018 | 3550 | 0.04 | Why? |
| Cell Adhesion | 1 | 2018 | 230 | 0.04 | Why? |
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 69 | 0.04 | Why? |
| BRCA1 Protein | 1 | 2017 | 102 | 0.04 | Why? |
| Mastectomy, Segmental | 1 | 2017 | 124 | 0.04 | Why? |
| MCF-7 Cells | 1 | 2017 | 199 | 0.04 | Why? |
| Radiotherapy, Adjuvant | 1 | 2018 | 180 | 0.04 | Why? |
| Religion | 1 | 2021 | 353 | 0.04 | Why? |
| Preoperative Period | 1 | 2018 | 271 | 0.04 | Why? |
| Receptors, Estrogen | 1 | 2017 | 171 | 0.04 | Why? |
| Radiometry | 1 | 2017 | 136 | 0.04 | Why? |
| Extracellular Matrix Proteins | 1 | 2017 | 95 | 0.04 | Why? |
| Lymphatic Metastasis | 1 | 2019 | 537 | 0.04 | Why? |
| Coculture Techniques | 1 | 2017 | 258 | 0.04 | Why? |
| Health Policy | 1 | 2017 | 6242 | 0.04 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.04 | Why? |
| Postoperative Period | 1 | 2018 | 651 | 0.04 | Why? |
| Microscopy, Electron, Transmission | 1 | 2018 | 605 | 0.04 | Why? |
| Immunoenzyme Techniques | 1 | 2018 | 448 | 0.04 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.04 | Why? |
| Molecular Sequence Annotation | 1 | 2018 | 478 | 0.04 | Why? |
| In Situ Hybridization | 1 | 2017 | 390 | 0.04 | Why? |
| Stem Cell Transplantation | 1 | 2021 | 531 | 0.04 | Why? |
| Bone Marrow | 1 | 2018 | 492 | 0.04 | Why? |
| Analysis of Variance | 1 | 2018 | 950 | 0.04 | Why? |
| Geography | 1 | 2021 | 1801 | 0.03 | Why? |
| Epithelial-Mesenchymal Transition | 1 | 2017 | 242 | 0.03 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Transcriptome | 2 | 2018 | 3466 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2021 | 23402 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.03 | Why? |
| User-Computer Interface | 1 | 2020 | 1068 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2017 | 1115 | 0.03 | Why? |
| Aged, 80 and over | 6 | 2018 | 88759 | 0.03 | Why? |
| Causality | 1 | 2017 | 857 | 0.03 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.03 | Why? |
| Bronchiectasis | 1 | 2017 | 312 | 0.03 | Why? |
| Stem Cells | 1 | 2018 | 595 | 0.03 | Why? |
| Surgical Wound Infection | 1 | 2017 | 501 | 0.03 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.03 | Why? |
| Hematologic Diseases | 1 | 2018 | 614 | 0.03 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.03 | Why? |
| Income | 1 | 2021 | 1564 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.03 | Why? |
| Mass Spectrometry | 1 | 2017 | 1165 | 0.03 | Why? |
| Down-Regulation | 1 | 2017 | 1416 | 0.03 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.03 | Why? |
| Adenocarcinoma | 1 | 2017 | 651 | 0.03 | Why? |
| Signal Transduction | 2 | 2018 | 7207 | 0.03 | Why? |
| Datasets as Topic | 1 | 2017 | 1404 | 0.03 | Why? |
| Pain | 1 | 2018 | 1084 | 0.03 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2017 | 1648 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.02 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.02 | Why? |
| Sequence Analysis, RNA | 1 | 2017 | 2290 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| HEK293 Cells | 1 | 2020 | 8394 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2018 | 3788 | 0.02 | Why? |
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 1692 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.02 | Why? |
| Emotions | 1 | 2018 | 2418 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Computational Biology | 1 | 2018 | 4514 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2017 | 15909 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.01 | Why? |